Search

Aldeyra Therapeutics Inc

Cerrado

1.67 -2.34

Resumen

Variación precio

24h

Actual

Mínimo

1.65

Máximo

1.6800000000000002

Métricas clave

By Trading Economics

Ingresos

-23T

-3.5M

BPA

-0.06

Empleados

7

EBITDA

3M

-2.9M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+18.34% upside

Dividendos

By Acuity

Próximas Ganancias

5 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

27M

125M

Apertura anterior

4.01

Cierre anterior

1.67

Aldeyra Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 jul 2026, 23:51 UTC

Bitcoin dips amid crypto volatility, while Ethereum rises; South Korea's GDP trends and geopolitical tensions raise concerns for regional market stability.

19 jul 2026, 23:51 UTC

"Bitcoin dips as Ethereum rises amid geopolitical tensions and South Korea's GDP data, with key economic indicators on the horizon."

19 jul 2026, 23:51 UTC

"Bitcoin Declines Amid Mixed Crypto Performance; South Korea's GDP and ASEAN Interest Rate Talks Signal Potential Market Shifts."

19 jul 2026, 23:51 UTC

Mixed cryptocurrency performance amid geopolitical tensions and economic uncertainties, with South Korea's GDP figures and rising U.S. margin debt raising investor concerns.

19 jul 2026, 23:51 UTC

Bitcoin is trading lower today, continuing a trend following Friday's declines in U.S. equity markets. It remains above its 20-day moving average.

19 jul 2026, 23:41 UTC

Canada's New Housing Price Index set for July 24, with a forecasted decline of -0.2% amid cautious market sentiment and ongoing economic pressures.

19 jul 2026, 23:21 UTC

Upcoming Chicago Fed National Activity Index release on July 23, 2026, may signal U.S. economic growth amidst mixed sentiment and inflation concerns.

19 jul 2026, 23:21 UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.4% in May Amid Cautious Optimism on Consumer Spending

19 jul 2026, 23:11 UTC

Correlated Moves

During after-market hours, SGD/CHF is higher, reflecting a slight gain since Friday's close. The asset exhibited notable volatility amid broader macroeconomic trends.

19 jul 2026, 23:11 UTC

ECB Expected to Maintain Interest Rate at 2.4% Amid Rising Energy Costs and Global Economic Concerns

19 jul 2026, 23:11 UTC

Euro Area's Deposit Facility Rate Expected to Hold Steady at 0.0225% Amid Cautious Market Sentiment and Geopolitical Tensions

19 jul 2026, 23:01 UTC

China's Loan Prime Rate Expected to Hold Steady at 3.50% Amid Cautious Economic Sentiment and Geopolitical Tensions Ahead of July Release

19 jul 2026, 23:01 UTC

China's Loan Prime Rate (LPR) 1Y release on July 20, 2026, forecasted at a cautious 0.03%, amid economic concerns impacting consumer spending and credit demand.

19 jul 2026, 23:01 UTC

After-market trading for GBP/ZAR shows gains since Friday's close, fluctuating throughout the session and remaining near the upper end of its one-month range.

19 jul 2026, 23:01 UTC

Macro News
Correlated Moves

GBP/USD declines in after-hours trading as the U.S. dollar strengthens against major currencies, reflecting broader investor sentiment and geopolitical tensions.

19 jul 2026, 23:01 UTC

GBP/CHF is higher in after-market trading, reaching the upper end of its one-month trading range despite no specific news identified for today's move.

19 jul 2026, 22:51 UTC

USD/NOK is trading higher in after-market hours, moving from a low to a high since Friday's close, despite remaining below its 20-day moving average.

19 jul 2026, 22:31 UTC

Japan's Inflation Rate Release on July 23, 2026: Market Eyes Potential Impact of Recent Economic Shifts and Extreme Weather on Monetary Policy.

19 jul 2026, 22:31 UTC

Japan's Core Inflation Rate Expected to Rise to 1.6% Amid Economic Concerns and Geopolitical Tensions Ahead of July Release

19 jul 2026, 22:21 UTC

GBP/NOK is higher in after-hours trading, reaching the upper end of its one-month range. No specific news was identified for this price move.

19 jul 2026, 22:21 UTC

EUR/SEK advanced in after-market trading, reaching a peak above previous levels. The performance contrasts with its position in the one-month trading range.

19 jul 2026, 22:21 UTC

Mortgage Rates Hit Nine-Month High at 6.65%, Raising Concerns Over Housing Affordability and Consumer Spending Ahead of Upcoming MBA Data Release

19 jul 2026, 22:21 UTC

Canada's June 2026 Inflation Rate Release Sparks Caution Amid Rising Gas Prices and Mixed Market Expectations

19 jul 2026, 22:21 UTC

Canada's Inflation Rate Expected to Decrease by 0.002% in June, Signaling Potential Deflationary Pressures Ahead of July Release

19 jul 2026, 22:21 UTC

Canada's Core Inflation Rate Release on July 20, 2026 Expected to Impact Monetary Policy Amid Ongoing Economic Pressures.

19 jul 2026, 22:21 UTC

Correlated Moves

Avalanche is declining during Sunday’s session, reflecting broader cryptocurrency market sentiment. The asset remains below its 20-day moving average.

19 jul 2026, 22:11 UTC

Correlated Moves

Gold/CAD is declining in the ongoing session, continuing a downward trend since Friday's close, with Silver also showing weakness.

19 jul 2026, 22:11 UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, reflecting a decline since Friday's close, influenced by a drop in Silver prices and macroeconomic factors.

19 jul 2026, 22:11 UTC

Correlated Moves

Gold/JPY is trading lower, continuing a decline since Friday's close. The asset remains below its 20-day moving average amid broader weakness in precious metals.

19 jul 2026, 22:11 UTC

Macro News

Crude oil prices are rising amid concerns over shipping route disruptions and escalating U.S.-Iran tensions. Prices have regained momentum above the 20-day moving average.

Comparación entre iguales

Cambio de precio

Aldeyra Therapeutics Inc previsión

Precio Objetivo

By TipRanks

18.34% repunte

Estimación a 12 Meses

Media 2 USD  18.34%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Aldeyra Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
help-icon Live chat